
In recent years, idiopathic inflammatory muscle disease assessment has advanced significantly with the development of an international consensus on outcome measurement indices. The International Myositis Assessment and Clinical Studies Group continues to evaluate the validity and reliability of various disease activity and disease damage tools, which will facilitate adequately controlled randomized trials of recently developed therapeutic agents.

